COMMENTARY

• With No Pilot at Helm, Pharma Industry Embroiled in Confusion with Voluntary Funding Disclosures
  September 1, 2014

• Wholesalers’ Q1 Earnings Remain Positive, Medical Fee Cut Rule Seen to Boost Accuracy of Financial Results in Sept.
  August 25, 2014

• Japanese Drug Makers Working to Increase Pace of Drug Discovery by Optimizing Operations at Research Centers
  August 18, 2014

• PMDA Sets Target Review Times for Partial Changes to Generic Approval - A New Way to Underpin Stable Supply
  August 4, 2014

• Competition Fuels Personalized Medicine Market, First-Line Positions Eyed for Xalkori, Alecensa
  July 28, 2014

• Can New Fast-Track Review System Perk Up Drug Makers’ Development Drive in Japan?
  July 7, 2014

• June Reimbursement Listing Could Mark Watershed in Japan Generic Market
  July 1, 2014

• Two Reasons MHLW Opposes Yearly NHI Price Revisions, “Annual” Dropped from Gov’t Policy Guidelines
  June 17, 2014

• Delicate Balancing Act Required for SGLT-2 Inhibitor Promotions - Safety vs Efficacy
  June 16, 2014

• Why Not Make RMPs for Existing Products as Differentiation Strategy?
  June 9, 2014

• 2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
  June 2, 2014

• Clinical Research Regulations at Crossroads: Guidelines or Legislation?
  May 26, 2014

• Was the Main Paper from VART Study “Practice” for a Grad Student?
  May 19, 2014

• Can CROs Become Independent Players? Compliance, Ethics Will Be Major Issues for Growing Industry
  April 28, 2014

• Industry Faces Tough Road to Institutionalization of Key Premium, Eligibility Up for Discussion
  April 21, 2014

• Approval of Novel Antiepileptic Drugs as Monotherapies Coming Closer to Reality
  April 7, 2014

• Will Japan NIH Initiative Create a “Japanese Model” that Overcomes Its Size Disadvantage?
  March 28, 2014

• CASE-J Flutter: Doesn’t Blopress Ad Overemphasize Its Benefits on Diabetes?
  March 19, 2014

• “Lack of Urgency” Leads to New Rule; Penalty for Low Price Settlement Rates May Have Been Inevitable
  March 12, 2014

• Hardships and Successes of Diversified Entrants Lead to Question: Will Pharmaceuticals Continue to Be a Growth Sector?
  March 5, 2014

ページ